KDM6A and malignant pleural mesothelioma: Dr. Cregan reported that preliminary testing of GSK-J1 on NCI-H226 cell proliferation showed that it could inhibit the growth of malignant pleural mesothelioma (MPM) cells with KDM6A mutations (28).